S-C08
Myeloproliferative Neoplasms: Biological and Therapeutic Advances

Track: BMT Tandem "Scientific" Meeting
Saturday, March 1, 2014: 10:30 AM-12:00 PM
Texas C (Gaylord Texan)
Chair:
Vikas Gupta, MD

Disclosures:
V. Gupta, Novartis, Advisory board: Advisory Board, Consultancy, Honoraria and Research Funding
Incyte, Advisory Board: Advisory Board and Honoraria

Biology of Stem Cells in Myelofibrosis
Ronald Hoffman, MD, Mount Sinai School of Medicine

Audio File Recorded Presentation
POINT/COUNTERPOINT: Is There a Role for HCT as Upfront Therapy for Myelofibrosis in the Era of JAK Inhibitors? Case Vignette
Vikas Gupta, MD, Princess Margaret Cancer Center

Audio File Recorded Presentation
POINT/COUNTERPOINT: Is There a Role for HCT as Upfront Therapy for Myelofibrosis in the Era of JAK Inhibitors? “No”
Srdan Verstovsek, MD, PhD, M.D. Anderson Cancer Center

Audio File Recorded Presentation
POINT/COUNTERPOINT: Is There a Role for HCT as Upfront Therapy for Myelofibrosis in the Era of JAK Inhibitors? "Yes"
H Joachim Deeg, MD, Fred Hutchinson Cancer Research Center

Audio File Recorded Presentation
See more of: BMT Tandem "Scientific" Meeting
<< Previous Session | Next Session >>